A NOVEL HUMAN LABORATORY MODEL FOR SCREENING MEDICATIONS FOR ALCOHOL USE DISORDER

用于筛选酒精使用障碍药物的新型人体实验室模型

基本信息

  • 批准号:
    10095672
  • 负责人:
  • 金额:
    $ 8.36万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2019
  • 资助国家:
    美国
  • 起止时间:
    2019-09-20 至 2022-08-31
  • 项目状态:
    已结题

项目摘要

Project Summary of Parent Grant: A Novel Human Laboratory Model for Screening Medications for Alcohol Use Disorder (R21AA027180) While developing novel medications to treat AUD remains a high research priority area, there are major opportunities to refine the process of screening novel compounds. To that end, a key question in clinical studies of novel compounds for AUD, is how to efficiently determine whether a novel medication has sufficient evidence of initial efficacy to warrant the conduct of subsequent clinical trials. The process of screening novel compounds for initial efficacy, known as the early phase 2 of medications development, often consists of human laboratory studies assessing constructs of putative clinical relevance, such as alcohol craving, subjective response to alcohol, and alcohol self-administration under laboratory conditions. Nevertheless, these controlled human laboratory models lack the ecological validity of clinical trials in which medication effects are established via clinically meaningful endpoints in individuals motivated to change their drinking. The scientific premise of the proposal is that screening novel AUD medications can be efficient and clinically meaningful if early phase 2 studies combine the internal validity of experimental laboratory testing with the external validity of clinical trials. To that end, we propose to conduct a novel early efficacy detection paradigm informed by the smoking cessation medication development literature, to screen both an established (naltrexone) and a promising (varenicline) AUD medication. Specifically, this novel human laboratory protocol involves a randomized, double-blind, placebo-controlled, 3-arm parallel group design, in which individuals with current AUD reporting intrinsic motivation to change their drinking complete a week-long “practice quit attempt” and cue-reactivity paradigm. The primary outcome is the number of abstinent days during the practice quit week under active medication compared to placebo. The proposed laboratory protocol has been developed and validated for screening smoking cessation pharmacotherapies. The objective of this protocol is to adapt and validate this novel approach to screen pharmacotherapies for AUD.
父母资助项目总结:一种用于筛选药物的新型人类实验室模型 酒精使用障碍(R21AA027180) 虽然开发治疗AUD的新型药物仍然是一个高度优先的研究领域,但主要 有机会改进筛选新化合物的过程。为此,临床上的一个关键问题 研究新的化合物对AUD,是如何有效地确定一种新的药物是否有足够的 初步疗效的证据,以保证后续临床试验的进行。筛选小说的过程 用于初始功效的化合物,称为药物开发的早期阶段2,通常由以下组成: 人类实验室研究评估推定的临床相关性的结构,如酒精渴望, 对酒精的主观反应和实验室条件下的酒精自我给药。然而,尽管如此, 这些受控的人类实验室模型缺乏临床试验的生态有效性, 通过有动机改变其饮酒的个体中的临床意义的终点来确定效果。的 该提案的科学前提是,筛选新型AUD药物可以是有效的, 如果早期2期研究联合收割机将实验室测试的内部效度与 临床试验的外部效度。为此,我们建议进行一种新的早期疗效检测范式 通过了解戒烟药物开发文献,筛选既有 (纳洛酮)和一种有前途的(伐尼克兰)AUD药物。具体来说,这个新的人类实验室协议 涉及随机化、双盲、安慰剂对照、3臂平行组设计,其中, 当前AUD报告的改变饮酒的内在动机完成了为期一周的“实践戒烟尝试” 和线索反应范式。主要结果是在练习戒烟期间的禁欲天数 与安慰剂相比,活性药物治疗的周数。拟定的实验室方案已经制定, 并被验证用于筛选戒烟药物疗法。本协议的目的是适应 并验证这种新的方法来筛选AUD的药物治疗。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

LARA A. RAY其他文献

LARA A. RAY的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('LARA A. RAY', 18)}}的其他基金

The effects of stress on decision-making in alcohol use disorder: A translational approach
压力对酒精使用障碍决策的影响:转化方法
  • 批准号:
    10667891
  • 财政年份:
    2023
  • 资助金额:
    $ 8.36万
  • 项目类别:
Translational underpinnings of motivation for alcohol in humans
人类饮酒动机的转化基础
  • 批准号:
    10345709
  • 财政年份:
    2023
  • 资助金额:
    $ 8.36万
  • 项目类别:
Integrating findings across stages of medication development for AUD
整合 AUD 药物开发各个阶段的发现
  • 批准号:
    10353926
  • 财政年份:
    2021
  • 资助金额:
    $ 8.36万
  • 项目类别:
A Novel Human Laboratory Model for Screening Medications for Alcohol Use Disorder
用于筛选酒精使用障碍药物的新型人体实验室模型
  • 批准号:
    10387543
  • 财政年份:
    2021
  • 资助金额:
    $ 8.36万
  • 项目类别:
A Randomized Controlled Clinical Trial of the Neuroimmune Modulator Ibudilast for the Treatment of Alcohol Use Disorder
神经免疫调节剂异丁司特治疗酒精使用障碍的随机对照临床试验
  • 批准号:
    10387454
  • 财政年份:
    2021
  • 资助金额:
    $ 8.36万
  • 项目类别:
Integrating findings across stages of medication development for AUD
整合 AUD 药物开发各个阶段的发现
  • 批准号:
    10491120
  • 财政年份:
    2021
  • 资助金额:
    $ 8.36万
  • 项目类别:
A Novel Human Laboratory Model for Screening Medications for Alcohol Use Disorder
用于筛选酒精使用障碍药物的新型人体实验室模型
  • 批准号:
    10019310
  • 财政年份:
    2019
  • 资助金额:
    $ 8.36万
  • 项目类别:
A randomized controlled clinical trial of the neuroimmune modulator ibudilast for the treatment of alcohol use disorder
神经免疫调节剂异丁司特治疗酒精使用障碍的随机对照临床试验
  • 批准号:
    9883692
  • 财政年份:
    2018
  • 资助金额:
    $ 8.36万
  • 项目类别:
Clinical neuroscience of alcoholism: integrating neuroscience and clinical trials
酗酒的临床神经科学:神经科学与临床试验的结合
  • 批准号:
    10242146
  • 财政年份:
    2018
  • 资助金额:
    $ 8.36万
  • 项目类别:
Clinical neuroscience of alcoholism: integrating neuroscience and clinical trials
酗酒的临床神经科学:神经科学与临床试验的结合
  • 批准号:
    10481839
  • 财政年份:
    2018
  • 资助金额:
    $ 8.36万
  • 项目类别:

相似海外基金

Collaborative Research: Overlooked Oxidation of Aqueous Alcohols: Kinetics, Mechanism, and Relevance to Water Reuse
合作研究:被忽视的水醇氧化:动力学、机制以及与水回用的相关性
  • 批准号:
    2304861
  • 财政年份:
    2023
  • 资助金额:
    $ 8.36万
  • 项目类别:
    Continuing Grant
STTR Phase I: Development of Modular Reactors to Convert Methane to Alcohols at Low Temperatures
STTR 第一阶段:开发在低温下将甲烷转化为醇的模块化反应器
  • 批准号:
    2151256
  • 财政年份:
    2023
  • 资助金额:
    $ 8.36万
  • 项目类别:
    Standard Grant
Development of amine-dehydrogenase and lyase biocatalysts for the sustainable manufacturing of unnatural chiral amino acids and amino alcohols
开发胺脱氢酶和裂解酶生物催化剂,用于可持续生产非天然手性氨基酸和氨基醇
  • 批准号:
    2870226
  • 财政年份:
    2023
  • 资助金额:
    $ 8.36万
  • 项目类别:
    Studentship
Collaborative Research: Overlooked Oxidation of Aqueous Alcohols: Kinetics, Mechanism, and Relevance to Water Reuse
合作研究:被忽视的水醇氧化:动力学、机制以及与水回用的相关性
  • 批准号:
    2304860
  • 财政年份:
    2023
  • 资助金额:
    $ 8.36万
  • 项目类别:
    Continuing Grant
Postdoctoral Fellowship: MPS-Ascend: Development of Selective Reaction Schemes for Photoactivation of Alcohols
博士后奖学金:MPS-Ascend:醇光活化选择性反应方案的开发
  • 批准号:
    2316541
  • 财政年份:
    2023
  • 资助金额:
    $ 8.36万
  • 项目类别:
    Fellowship Award
Development of phosphorylation of alcohols in protein based on the structural modification of phosphoenolpyruvate
基于磷酸烯醇丙酮酸结构修饰的蛋白质醇磷酸化研究进展
  • 批准号:
    22KJ1152
  • 财政年份:
    2023
  • 资助金额:
    $ 8.36万
  • 项目类别:
    Grant-in-Aid for JSPS Fellows
Nickel Cross-Coupling Cascades with α-Heteroatom Radicals to Prepare Sterically Hindered Alcohols and Amines
镍与α-杂原子自由基交叉偶联级联制备位阻醇和胺
  • 批准号:
    10604535
  • 财政年份:
    2023
  • 资助金额:
    $ 8.36万
  • 项目类别:
Towards a better understanding of the effect of the pentafluorosulfanyl group on the lipophilicity and acid/base properties of alcohols and amines
更好地了解五氟硫基对醇和胺的亲脂性和酸/碱性质的影响
  • 批准号:
    571856-2021
  • 财政年份:
    2022
  • 资助金额:
    $ 8.36万
  • 项目类别:
    Alliance Grants
Pd-Catalyzed C(sp3)-H Functionalizations Directed by Free Alcohols and Boc-Protected Amines
由游离醇和 Boc 保护的胺引导的 Pd 催化 C(sp3)-H 官能化
  • 批准号:
    10606508
  • 财政年份:
    2022
  • 资助金额:
    $ 8.36万
  • 项目类别:
MPS-Ascend: Nickel/Photoredox-Catalyzed C(sp3)–C(sp3) Cross-Coupling Between Alkyl Halides and Activated Alcohols
MPS-Ascend:镍/光氧化还原催化的 C(sp3)→C(sp3) 烷基卤化物和活化醇之间的交叉偶联
  • 批准号:
    2213210
  • 财政年份:
    2022
  • 资助金额:
    $ 8.36万
  • 项目类别:
    Fellowship Award
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了